The association of toxicities and outcomes with circulating endothelial cells (CEC) in non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (Bev).

被引：0
|
作者：
Sadraei, Nooshin Hashemi
Du, Lingling
Yadav, Ruchi
Grane, Ronald
Jacobs, Barbara
Hamulak, John
Ma, Patrick C.
Pennell, Nathan A.
Elson, Paul
Borden, Ernest C.
机构：
[1] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Cleveland Clin, Cleveland, OH USA
[3] Cleveland Clin, Cleveland, OH 44106 USA
[4] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[5] Case Comprehens Canc Ctr, Cleveland, OH USA
[6] Cleveland Clin Fdn, Dept Translat Hematol & Oncol Res, Cleveland, OH 44195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19012
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Immunotherapy in previously treated non-small cell lung cancer (NSCLC)
    Leal, Ticiana A.
    Ramalingam, Suresh S.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S422 - S432
  • [42] SYSTEMIC BEVACIZUMAB (BEV) FOR LEPTOMENINGEAL DISEASE (LMD) FROM NON-SMALL CELL LUNG CANCER
    Carlo, Maria
    Omuro, Antonio
    Grommes, Christian
    Kris, Mark
    Nolan, Craig
    Pentsova, Elena
    Pietanza, Maria
    Kaley, Thomas
    NEURO-ONCOLOGY, 2013, 15 : 104 - 104
  • [43] Bevacizumab in Non-Small Cell Lung Cancer
    Francesco Di Costanzo
    Francesca Mazzoni
    Marinella Micol Mela
    Lorenzo Antonuzzo
    Daniele Checcacci
    Matilde Saggese
    Federica Di Costanzo
    Drugs, 2008, 68 : 737 - 746
  • [44] Bevacizumab in non-small cell lung cancer
    Di Costanzo, Francesco
    Mazzoni, Francesca
    Mela, Marinella Micol
    Antonuzzo, Lorenzo
    Checcacci, Daniele
    Saggese, Matilde
    Di Costanzo, Federica
    DRUGS, 2008, 68 (06) : 737 - 746
  • [45] NRAS mutated non-small cell lung cancer (NSCLC) patients: Characteristics and outcomes
    Dehem, A.
    Mazieres, J.
    Chour, A.
    Guisier, F.
    Ferreira, M.
    Boussageon, M.
    Girard, N.
    Moro-Sibilot, D.
    Cadranel, J.
    Zalcman, G.
    Ricordel, C.
    Wislez, M.
    Munck, C.
    Poulet, C-H.
    Gauvain, C.
    Descarpentries, C.
    Wasielewski, E.
    Cortot, A. B.
    Baldacci, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1023 - S1024
  • [46] Reporting of patient reported outcomes in randomized clinical trials (RCTs) in non-small cell lung cancer (NSCLC) patients (pts)
    Palmeri, Laura
    Derkach, Sergii
    Mazur-Janik, Ewelina
    Soman, Arundhati
    Alves, Catarina Ribeiro
    Shah, Radhika
    Vidal-Fisher, Liat
    Shahmarvand, Nahid
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Natural history, treatment (tx) patterns, and outcomes in MET dysregulated non-small cell lung cancer (NSCLC) patients (pts)
    Wolf, J.
    Baik, C.
    Heist, R. S.
    Neal, J. W.
    Mansfield, A. S.
    Buettner, R.
    Davis, K. L.
    Giovannini, M.
    Mutebi, A.
    Awad, M. M.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E131 - E131
  • [48] Bevacizumab in non-small cell lung cancer
    Sandler, Alan
    CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4613S - 4616S
  • [49] Impact of age on outcomes with PD-(L)1 blockade in patients (Pts) with non-small cell lung cancer (NSCLC).
    Lichtenstein, Morgan
    Nipp, Ryan David
    Goodwin, Kelly
    Anderson, Danyon
    Newcomb, Richard
    Gainor, Justin F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Non-small cell lung cancer (NSCLC) in elderly patients
    Batura-Gabryel, H.
    Brajer, B.
    LUNG CANCER, 2006, 52 : S19 - S19
12345